Astellas to Pay Aveo as Much as $1.3 Billion for Kidney Cancer Medicine

Aveo Pharmaceuticals Inc. gained as much as 15 percent in Nasdaq trading after Astellas Pharma Inc. agreed to pay as much as $1.3 billion for the rights to develop and sell an experimental cancer treatment that may compete with medicines from Pfizer Inc. and Bayer AG.
Bloomberg